Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V0002 CA plus Niaspan for niacin-induced flushing and lipid effects in dyslipidemia
2007-006393-29Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia and hypertriglyceridemia comparing V0002 CA plus Niaspan with Placebo plus Niaspan (2 arms). Primary endpoints: Niacin-induced flushing prevention and Change in lipid parameters. Started Feb 2008; status: completed.
02
Drugs
omega-3-acid ethyl esters
03
Conditions
dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on 2007-006393-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006393-29.